

EVscale™ - Addressing
significant unmet medical
needs with therapeutic EVs





Diabetic/Chronic Wound Treatment

Medical Need

- Diabetes prevalence worldwide: 589 m (2025) and rising*
- 19-34% of diabetics develop diabetic foot ulcers in their lifetime
- 4-8% of diabetics (20% of foot ulcer patients) suffer from limb amputations, resulting in loss of QoL and huge societal burden
- Currently no efficacious and approved treatments

Pre-clinical proof-of-concept data for EVscale™-EV preps in wound treatment



Conclusions

- EV from EVscale™ show tremendous potential in preclinical models of wound treatment
- Innovative hydrogel formulations developed by Gipfel Life Sciences (DCML7 #2) are further enhancing the treatment effect in a diabetic mouse model with almost complete wound closure at day 16

In collaboration with

GIPFEL
LIFE SCIENCES